{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Liver+Disease+or+Abnormalities&page=2", "query": { "condition": "Liver Disease or Abnormalities", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 46, "total_pages": 5, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Liver+Disease+or+Abnormalities&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Liver+Disease+or+Abnormalities&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-08T03:23:54.425Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02076906", "title": "MR-guided High Intensity Focused Ultrasound (HIFU) on Pediatric Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Relapsed Pediatric Solid Tumors", "Refractory Pediatric Solid Tumors", "Rhabdomyosarcoma", "Ewing Sarcoma", "Osteosarcoma", "Neuroblastoma", "Wilms Tumor", "Hepatic Tumor", "Germ Cell Tumor", "Desmoid Tumor" ], "interventions": [ { "name": "Magnetic Resonance High Intensity Focused Ultrasound", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "AeRang Kim", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "30 Years", "sex": "ALL", "summary": "Up to 30 Years" }, "enrollment_count": 7, "start_date": "2014-04", "completion_date": "2024-11-24", "has_results": false, "last_update_posted_date": "2025-01-01", "last_synced_at": "2026-10-08T03:23:54.425Z", "location_count": 2, "location_summary": "Washington D.C., District of Columbia • Cincinnati, Ohio", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02076906" }, { "nct_id": "NCT07820085", "title": "A Study to Investigate PORT-77 Oral Dosing Compared With Placebo in Participants With Erythropoietic Protoporphyria (EPP) or X-linked Protoporphyria (XLP)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Erythropoietic Protoporphyria (EPP)", "X-Linked Protoporphyria (XLP)", "EPP2" ], "interventions": [ { "name": "PORT-77", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Portal Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 225, "start_date": "2026-09", "completion_date": "2029-09", "has_results": false, "last_update_posted_date": "2026-09-15", "last_synced_at": "2026-10-08T03:23:54.425Z", "location_count": 2, "location_summary": "Huntington Beach, California • Cincinnati, Ohio", "locations": [ { "city": "Huntington Beach", "state": "California" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT07820085" }, { "nct_id": "NCT00003926", "title": "Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Brain and Central Nervous System Tumors", "Childhood Germ Cell Tumor", "Chordoma", "Kidney Cancer", "Liver Cancer", "Neuroblastoma", "Ovarian Cancer", "Retinoblastoma", "Sarcoma" ], "interventions": [ { "name": "amifostine trihydrate", "type": "DRUG" }, { "name": "busulfan", "type": "DRUG" }, { "name": "filgrastim", "type": "DRUG" }, { "name": "melphalan", "type": "DRUG" }, { "name": "thiotepa", "type": "DRUG" }, { "name": "peripheral blood stem cell transplantation (PBSC)", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Masonic Cancer Center, University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "45 Years", "sex": "ALL", "summary": "1 Year to 45 Years" }, "enrollment_count": 13, "start_date": "1998-11", "completion_date": "2003-08", "has_results": false, "last_update_posted_date": "2017-11-29", "last_synced_at": "2026-10-08T03:23:54.425Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003926" }, { "nct_id": "NCT00788125", "title": "Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Brain and Central Nervous System Tumors", "Childhood Germ Cell Tumor", "Extragonadal Germ Cell Tumor", "Kidney Cancer", "Liver Cancer", "Lymphoma", "Neuroblastoma", "Ovarian Cancer", "Sarcoma", "Testicular Germ Cell Tumor", "Unspecified Childhood Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "carboplatin", "type": "DRUG" }, { "name": "dasatinib", "type": "DRUG" }, { "name": "etoposide phosphate", "type": "DRUG" }, { "name": "ifosfamide", "type": "DRUG" }, { "name": "microarray analysis", "type": "GENETIC" }, { "name": "western blotting", "type": "GENETIC" }, { "name": "immunohistochemistry staining method", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "therapeutic conventional surgery", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "GENETIC", "OTHER", "PROCEDURE", "RADIATION" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "25 Years", "sex": "ALL", "summary": "1 Year to 25 Years" }, "enrollment_count": 7, "start_date": "2008-09-03", "completion_date": "2022-07-30", "has_results": true, "last_update_posted_date": "2023-07-14", "last_synced_at": "2026-10-08T03:23:54.425Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00788125" }, { "nct_id": "NCT06389877", "title": "A Study to Evaluate the Safety and Efficacy of BEAM-302 in Adult Patients With Alpha-1 Antitrypsin Deficiency (AATD)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Alpha 1-Antitrypsin Deficiency" ], "interventions": [ { "name": "BEAM-302", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Beam Therapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 192, "start_date": "2024-06-19", "completion_date": "2030-05", "has_results": false, "last_update_posted_date": "2026-10-05", "last_synced_at": "2026-10-08T03:23:54.425Z", "location_count": 3, "location_summary": "Birmingham, Alabama • Boston, Massachusetts • Charleston, South Carolina", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Charleston", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT06389877" }, { "nct_id": "NCT00101270", "title": "Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Childhood Burkitt Lymphoma", "Childhood Central Nervous System Germ Cell Tumor", "Childhood Diffuse Large Cell Lymphoma", "Childhood Grade III Lymphomatoid Granulomatosis", "Childhood Immunoblastic Large Cell Lymphoma", "Recurrent Childhood Brain Stem Glioma", "Recurrent Childhood Cerebellar Astrocytoma", "Recurrent Childhood Cerebral Astrocytoma", "Recurrent Childhood Ependymoma", "Recurrent Childhood Grade III Lymphomatoid Granulomatosis", "Recurrent Childhood Large Cell Lymphoma", "Recurrent Childhood Liver Cancer", "Recurrent Childhood Lymphoblastic Lymphoma", "Recurrent Childhood Malignant Germ Cell Tumor", "Recurrent Childhood Medulloblastoma", "Recurrent Childhood Rhabdomyosarcoma", "Recurrent Childhood Small Noncleaved Cell Lymphoma", "Recurrent Childhood Soft Tissue Sarcoma", "Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor", "Recurrent Childhood Visual Pathway Glioma", "Recurrent Colon Cancer", "Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor", "Recurrent Melanoma", "Recurrent Nasopharyngeal Cancer", "Recurrent Neuroblastoma", "Recurrent Osteosarcoma", "Recurrent Wilms Tumor and Other Childhood Kidney Tumors", "Recurrent/Refractory Childhood Hodgkin Lymphoma", "Unspecified Childhood Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "irinotecan hydrochloride", "type": "DRUG" }, { "name": "oxaliplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "21 Years", "sex": "ALL", "summary": "1 Year to 21 Years" }, "enrollment_count": 24, "start_date": "2005-03", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-06-05", "last_synced_at": "2026-10-08T03:23:54.425Z", "location_count": 1, "location_summary": "Arcadia, California", "locations": [ { "city": "Arcadia", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00101270" }, { "nct_id": "NCT01403402", "title": "Congenital Muscle Disease Study of Patient and Family Reported Medical Information", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Congenital Muscular Dystrophy With ITGA7 (Integrin Alpha-7) Deficiency", "Alpha-Dystroglycanopathy (Congenital Muscular Dystrophy and Abnormal Glycosylation of Dystroglycan With Severe Epilepsy)", "Alpha-Dystroglycanopathy (Congenital Muscular Dystrophy With Fatty Liver and Infantile-onset Cataract Caused by TRAPPC11 Mutations)", "Alpha-Dystroglycanopathy (Congenital Muscular Dystrophy With Hypoglycosylation of Dystroglycan)", "Alpha-Dystroglycanopathy (Congenital Muscular Dystrophy With Hypoglycosylation of Dystroglycan and Epilepsy)", "Alpha-Dystroglycanopathy (Dystroglycanopathy, Congenital With or Without Mental Retardation (Formerly MDC1C))", "Alpha-Dystroglycanopathy (Fukuyama CMD)", "Alpha-Dystroglycanopathy (LGMDR09 FKRP Related (Formerly LGMD2I))", "Alpha-Dystroglycanopathy (LGMDR11 POMT1 Related (Formerly LGMD2K))", "Alpha-Dystroglycanopathy (LGMDR13 FKTN Related (Formerly LGMD2M))", "Alpha-Dystroglycanopathy (LGMDR14 POMT2 Related (Formerly LGMD2N))", "Alpha-Dystroglycanopathy (LGMDR15 POMGnT1 Related (Formerly LGMD2O))", "Alpha-Dystroglycanopathy (LGMDR19 GMPPB Related (Formerly LGMD2T))", "Alpha-Dystroglycanopathy (LGMDR20 ISPD Related (Formerly LGMD2U))", "Alpha-Dystroglycanopathy (LGMDR24 POMGnT2 Related)", "Alpha-Dystroglycanopathy (Muscle Eye Brain Disease (MEB))", "Alpha-Dystroglycanopathy (Walker Warburg Syndrome (WWS))", "Choline Kinase B Receptor - CHKB", "Collagen VI Related Disorders", "Collagen XII Related Disorders", "Congenital Muscular Dystrophy Not Otherwise Specified (Including Merosin Positive)", "Congenital Muscular Dystrophy With Cataracts and Intellectual Disability (MDCCAID)", "Congenital Muscular Dystrophy With Joint Hyperlaxity", "Congenital Muscular Dystrophy With Rigid Spine Related to ACTA1", "Emery-Dreifuss Muscular Dystrophy", "GOLGA2-related Congenital Muscle Dystrophy With Brain Involvement", "LMNA Related Disorders", "Merosin Deficient CMD (Full or Partial)", "Nesprin Related MD (SYNE1)", "SELENON Related Disorders (Previously Known as SEPN1)", "SELENON Related Myopathy (Aka SEPN1)", "Telethonin CMD", "Congenital Myasthenic Syndrome", "Limb-Girdle Muscular Dystrophy", "LGMDD01 - DNAJB6 (Formerly LGMD1D)", "LGMDD05 - Collagen VI Related Bethlem Myopathy (Dominant)", "LGMDR07 - Telethonin (TCAP) Related (Formerly LGMD2G)", "LGMDR08 - TRIM Related (Formerly LGMD2H)", "LGMDR09 - FKRP Related (Formerly LGMD2I)", "LGMDR10 - Titin (TTN) Related (Formerly LGMD2J)", "LGMDR11 - POMT1 Related (Formerly LGMD2K)", "LGMDR13 - Fukutin (FKTN) Related (Formerly LGMD2M)", "LGMDR14 - POMT2 Related (Formerly LGMD2N)", "LGMDR15 - POMGnT1 Related (Formerly LGMD2O)", "LGMDR16 - DAG1 Related Dystroglycanopathy (Formerly LGMD2P)", "LGMDR17 - Plectin (PLEC) Related (Formerly LGMD2Q)", "LGMDR18 - TRAPPC11 Related (Formerly LGMD2S)", "LGMDR19 - GMPPB Related (Formerly LGMD2T)", "LGMDR20 - ISPD Related (Formerly LGMD2U)", "LGMDR22 - Collagen VI Related Bethlem Myopathy (Recessive)", "LGMDR23 - LAMA2 Related", "LGMDR24 - POMGnT2 Related" ], "interventions": [], "intervention_types": [], "sponsor": "Cure CMD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 4000, "start_date": "2009-09", "completion_date": "2029-09", "has_results": false, "last_update_posted_date": "2021-08-09", "last_synced_at": "2026-10-08T03:23:54.425Z", "location_count": 1, "location_summary": "Lakewood, California", "locations": [ { "city": "Lakewood", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01403402" }, { "nct_id": "NCT00030108", "title": "Ixabepilone in Treating Young Patients With Solid Tumors or Leukemia That Haven't Responded to Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Brain and Central Nervous System Tumors", "Childhood Germ Cell Tumor", "Extragonadal Germ Cell Tumor", "Kidney Cancer", "Leukemia", "Liver Cancer", "Neuroblastoma", "Ovarian Cancer", "Sarcoma", "Unspecified Childhood Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "ixabepilone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institutes of Health Clinical Center (CC)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "21 Years", "sex": "ALL", "summary": "2 Years to 21 Years" }, "enrollment_count": 30, "start_date": "2001-11", "completion_date": "2010-04", "has_results": false, "last_update_posted_date": "2012-03-15", "last_synced_at": "2026-10-08T03:23:54.425Z", "location_count": 2, "location_summary": "Washington D.C., District of Columbia • Bethesda, Maryland", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00030108" }, { "nct_id": "NCT00303940", "title": "Talabostat Combined With Temozolomide or Carboplatin in Treating Young Patients With Relapsed or Refractory Brain Tumors or Other Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Brain and Central Nervous System Tumors", "Childhood Germ Cell Tumor", "Kidney Cancer", "Liver Cancer", "Neuroblastoma", "Ovarian Cancer", "Sarcoma", "Unspecified Childhood Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "carboplatin", "type": "DRUG" }, { "name": "talabostat mesylate", "type": "DRUG" }, { "name": "temozolomide", "type": "DRUG" }, { "name": "pharmacological study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Institutes of Health Clinical Center (CC)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "18 Years", "sex": "ALL", "summary": "2 Years to 18 Years" }, "enrollment_count": 26, "start_date": "2005-12", "completion_date": "2010-02", "has_results": false, "last_update_posted_date": "2012-03-15", "last_synced_at": "2026-10-08T03:23:54.425Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00303940" }, { "nct_id": "NCT04791228", "title": "A Pilot Study of Thermodox and MR-HIFU for Treatment of Relapsed Solid Tumors", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Solid Tumors", "Soft Tissue Sarcoma", "Ewing Sarcoma", "Malignant Epithelial Neoplasm", "Rhabdomyosarcoma", "Wilms Tumor", "Hepatic Tumor", "Germ Cell Tumor", "Bone Metastases" ], "interventions": [ { "name": "Magnetic Resonance-Guided High Intensity Focused Ultrasound", "type": "DEVICE" }, { "name": "Lyso-thermosensitive Liposomal Doxorubicin", "type": "DRUG" } ], "intervention_types": [ "DEVICE", "DRUG" ], "sponsor": "Children's National Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 0, "start_date": "2022-11-10", "completion_date": "2024-12-23", "has_results": false, "last_update_posted_date": "2025-01-01", "last_synced_at": "2026-10-08T03:23:54.425Z", "location_count": 1, "location_summary": "Washington D.C., District of Columbia", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04791228" } ] }